New four-year initiative targets cardiovascular-kidney-metabolic syndrome

FHS
July 18, 2024
10:39 pm

About 1 in 3 U.S. adults have at least three risk factors for cardiovascular-kidney-metabolic (CKM) syndrome, a health disorder related to the strong connections among cardiovascular disease, kidney disease and metabolic disease (such as Type 2 diabetes and obesity).

New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors

Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

November 4, 2024

KB-707 by Krystal Biotech for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 28, 2023

Metsera partners with Amneal to manufacture obesity drugs, and Clive Meanwell hands over CEO role

Obesity startup Metsera is getting a new manufacturing partner and a new CEO. On Tuesday, the well-funded startup announced that it would bring on specialty

October 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.